All Pharmaceutical Microbiology articles – Page 2
-
NewsTB and HIV treatments are not enough for a full recovery
Existing treatments control TB and HIV, but the immune system does not revert to normal, helping explain why people living with HIV remain susceptible to infections and underscoring the need for immunotherapies.
-
NewsWhy don’t antibiotic-making bacteria self-destruct?
Scientists discovered a promising new antibiotic in a soil sample. The molecule, lariocidin, is produced by the microbe Paenibacillus and shows broad activity against pathogenic bacteria. Now, the researchers report how Paenibacillus avoids harm by its own antibiotic.
-
NewsInjectable hydrogel-mediated co-delivery of oncolytic adenovirus and melphalan for retinoblastoma control and vision preservation
The collagen-based hydrogel enabled controlled oncolytic adenovirus and melphalan release and sustained retention. This approach eradicated retinoblastoma tumors and restored normal ocular structure and visual function following intravitreal administration.
-
NewsClinical trial in Ethiopia targets the trachoma scourge
A new study documents the outcomes of an evaluation of fluorometholone as adjunctive medical therapy for trachomatous trichiasis surgery, part of an initiative to better prevent blindness and improve quality of life for those affected.
-
NewsResearchers revive failing antibiotics with two-faced Janus nanoparticles
Researchers have restored the power of failing antibiotics by combining them with two-sided nanoparticles, ultra-small building blocks of materials less than 100 nanometers across. The nanoparticles showed a remarkable ability to compromise bacterial cell walls, leaving them vulnerable to attack.
-
NewsTraditional herb offers new hope for antibiotic-free pig farming
A new review highlights that Houttuynia cordata extract could serve as a multifunctional natural substitute for antibiotics in swine production. Plant-derived flavonoids, volatile oils, and polysaccharides suppress pathogens including Salmonella, PRRSV, and Streptococcus suis.
-
NewsNew test shows which antibiotics actually work
Drugs that act against bacteria are mainly assessed based on how well they inhibit bacterial growth under laboratory conditions. A critical factor is whether the active substances actually kill the pathogens in the body. Researchers have presented a new method for measuring how effectively antibiotics kill bacteria.
-
NewsA new ally against tooth decay: Arginine offers sweet relief
A new human clinical trial finds arginine can prevent caries due to bacterial plaques by reducing the acidity, altering the plaque structure and reducing harmful bacteria in the plaques.
-
NewsPlant-derived phenolic acids revive the power of tetracycline against drug-resistant bacteria
A study demonstrates that plant-derived phenolic acids can act as powerful antibiotic adjuvants by restoring and enhancing tetracycline efficacy against multidrug-resistant bacteria through multi-target disruption of key resistance mechanisms.
-
NewsDiscovery could lead to new treatments for drug-resistant fungal infections
Researchers have identified a molecule that may help turn the tide on fungal infections — butyrolactol A, a chemical compound that targets a deadly, disease-causing fungi called Cryptococcus neoformans.
-
NewsNew clinical standards strengthen antimicrobial stewardship in tuberculosis care
An international panel of experts from 32 countries has presented specific antimicrobial stewardship standards for TB care for the first time.
-
NewsHigh-dose antibiotic does not reduce mortality in tuberculous meningitis
The first trial examining the effects of higher rifampicin doses on tuberculosis survival has been completed. The study found no evidence of a beneficial effect from high-dose rifampicin.
-
NewsResearchers use robotics to find potential new antibiotic among hundreds of metal complexes
Researchers have used a cutting-edge robotic system capable of synthesising hundreds of metal complexes to develop a possible antibiotic candidate - offering fresh hope in the global fight against drug-resistant infections.
-
NewsThe antibiotic delafloxacin emerges as a potential therapeutic alternative against Legionella
A study shows, in an experimental laboratory model, that delafloxacin inhibits the intracellular replication of Legionella more effectively than one of the current standard treatments.
-
NewsEvaluation of antiviral activity of organic–polyoxometalate hybrids based on berberine against encephalomyocarditis virus in vitro
A new study promotes the development of POM-based drugs for clinical application by controlling the organic cations on the surface of organic–POM hybrids, ultimately yielding new POM drugs with high efficiency and low toxicity.
-
NewsNew antimalarial drug candidate shows potential for fighting resistance and reducing malaria transmission
Researchers have developed a new antimalarial drug candidate designed to address the growing challenge of drug resistance and potentially reduce malaria transmission.
-
NewsCancer-fighting bacterial product ‘cocktails’ may offer personalized treatment
Bacteria may be the next frontier in cancer treatment, according to researchers who devised a new approach of creating bacteria-derived mixtures — or cocktails — to help fight bladder cancer. They found that the cocktails significantly boost the immune system’s ability to fight cancer.
-
NewsResearchers see dramatic drop in HIV-infected immune cells in patient after cancer treatment received
Researchers report they may have taken an early step toward a more practical HIV cure. They focused on a patient undergoing cancer treatment and also living with HIV, who after receiving chemotherapy, had a significant reduction in the number of CD4+ T immune cells that contained an HIV provirus.
-
NewsStrategic advancement of second-generation fungal vaccine VXV-01 through Phase 1 trials
The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) have announced that the second-generation fungal vaccine candidate known as VXV‑01 is poised to move forward in development up to and including Phase 1 clinical evaluation.
-
NewsMutated baker’s yeast at the forefront of petroleum substitute tech
Researchers engineering Saccharomyces cerevisiae to produce 2,3-butanediol (2,3-BDO) introduced mutations into the genomic DNA. The researchers engineered four altered strains and subjected them to ethanol, heat, and low pH stressors.